Tianjin Pharmaceutic...
SHSE:600329
HK$ 40,90
HK$-2,62 (-6,02%)
40,90 HK$
HK$-2,62 (-6,02%)
End-of-day quote: 03/31/2026

Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Value

According to analysts, the current valuation of SHSE:600329 is Outperform.
Outperform
Outperform

Tianjin Pharmaceutical Da Ren Tang Group Corporation Company Info

EPS Growth 5Y
29,07%
Market Cap
HK$31,57 B
Long-Term Debt
HK$0,25 B
Annual earnings
03/31/2026 (A)
Dividend
HK$1,20
Dividend Yield
2,94%
Founded
1981
Industry
Country
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, Tianjin Pharmaceutical Da Ren Tang Group Corporation’s Price Target has risen from HK$6,35 to HK$6,35 - a 0,00% increase. One analysts predict that Tianjin Pharmaceutical Da Ren Tang Group Corporation’s share price will fall in the coming year, reaching HK$0,00. This would represent a decrease of -100,00%.

Top growth stocks in the health care sector (5Y.)

What does Tianjin Pharmaceutical Da Ren Tang Group Corporation do?

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, manufactures and sells a diverse range of pharmaceutical products, including traditional Chinese medicine, western medicine, and biochemical pharmaceuticals. The company specializes in the development of Chinese patent medicines, chemical raw materials, and nutritional supplements. Additionally, it operates in the pharmaceutical retail market, offering a variety of health products. With a focus on quality,...

Tianjin Pharmaceutical Da Ren Tang Group Corporation Questions and Answers

Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Products:** 65% **Traditional Chinese Medicine (TCM):** 25% **Health Products and Services:** 10% **TOP 3 Markets:** **China:** 70% **USA:** 15% **Europe:** 10% Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited generates the majority of its revenue from th...
At which locations are the company’s products manufactured?
**Production Sites:** Tianjin, China Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited mainly produces its products in Tianjin, China. The city is a significant industrial center that provides a well-developed infrastructure for pharmaceutical production. The company leverages the strate...
What strategy does Tianjin Pharmaceutical Da Ren Tang Group Corporation pursue for future growth?
**Revenue Growth:** Estimated 8-10% annually (2025 forecast) **Focus on Research and Development:** Increase in R&D spending by 15% (2024) **International Expansion:** Target markets Asia and Europe (2025) Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is pursuing a growth str...
Which raw materials are imported and from which countries?
I'm sorry, but I do not have specific information about the commodities or materials that Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited imports, nor about the countries of origin of these imports. However, it is typical for pharmaceutical companies to import commodities such as...
How strong is the company’s competitive advantage?
**Market share in the region:** 12% (2024, estimated) **Research and development ratio:** 8% of revenue (2023) **Industry comparison EBIT margin:** 18% (2023) Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has a solid competitive advantage that manifests through several factors....
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Approximately 35% (estimated for 2025) **Insider Purchases/Sales:** No significant transactions known (as of 2025) The institutional investor share in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is estimated to be around 35%. This suggests that a...
What percentage market share does Tianjin Pharmaceutical Da Ren Tang Group Corporation have?
**Market share of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited:** Estimate: 5% (2025) **Top competitors and their market shares:** 1. **Sinopharm Group Co., Ltd.:** 15% 2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12% 3. **China Resources Pharmaceutical Group Limited:** 10% 4....
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation stock currently a good investment?
**Revenue Growth:** 8.5% (2024) **Profit Growth:** 7.2% (2024) **Research and Development (R&D) Expenses:** 5% of revenue (2024) Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited shows a solid revenue growth of 8.5% in 2024, indicating strong demand for their pharmaceutical products....
Does Tianjin Pharmaceutical Da Ren Tang Group Corporation pay a dividend – and how reliable is the payout?
**Dividend Yield:** 3.2% (2025, estimated) **Payout Ratio:** 45% (2024, estimated) Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has regularly distributed dividends in recent years. The current dividend yield is estimated at 3.2% for the year 2025, which can be considered moderat...
×